T-cell receptors and ICAM-1 expression in renal allografts during rejection

W. Moolenaar¹, J. A. Bruijn², E. Schrama¹, S. Ferrone⁴, M. R. Daha¹, A. H. Zwinderman³, P. J. Hoedemaeker², L. A. van Es¹, and F.J. van der Woude¹

¹ Department of Nephrology, ² Department of Pathology, and ³ Department of Biostatistics, University Hospital, Rijnsburgerweg 10, NL-2333 AA Leiden, The Netherlands

Department of Microbiology and Immunology, New York Medical College, Valhalla, NY 10595, USA

Received October 4, 1990/Received after revision February 1, 1991/Accepted February 7, 1991

Abstract. Sixty-two biopsies taken from 38 kidney grafts were studied for 15 histological and 10 immunohistological parameters. The biopsies were divided into three groups, according to the clinical diagnosis at the time they were performed: group 1, rejection (n = 43); group 2, other causes of dysfunction (n = 10); and group 3, stable function (n = 9). Histological signs of acute rejection included diffuse interstitial infiltrate, tubular basement membrane damage, mononuclear leukocyte infiltration, and congestion of the peritubular capillaries. Immunoperoxidase staining with monoclonal antibodies to ten markers showed a statistically significant association between detection of T-cell receptor subunits alpha-beta (TcR2) and gamma-delta (TcR1) on infiltrating lymphocytes and of intercellular adhesion molecule-1 (ICAM-1) in tubular cells and acute rejection. These results suggest that T-cell receptors and ICAM-1 may be useful markers to differentiate acute rejection from renal graft dysfunctions due to other abnormalities.

Key words: T-cell receptors, kidney transplantation, rejection - Rejection, kidney, T-cell receptors - ICAM, expression, kidney transplantation, rejection

Alloantigens mismatched between a transplanted kidney and a recipient may trigger a cascade of immune reactions that start with the interaction of the donor-type antigenpresenting cell with the host CD4 + helper T cell [13]. CD8 + cytotoxic T-cell responses are generated [4, 14] and activated CD4 + and CD8 + T cells eventually produce lymphokines such as gamma interferon and interleukin-2 [6]. Clonal proliferation of antigen-reactive T cells may ensue, with a subsequent development of cytotoxic T cells. They lyse their targets via a series of events involving nonspecific adhesion, specific recognition, and triggering of the T-cell lytic machinery. Lymphokines generated in situ can attract and activate [12] other poten-

Offprint requests to: F.J. van der Woude

tial effector cells, such as natural killer (NK) cells and monocytes/macrophages. Moreover, they can induce or upregulate the expression of target cell antigens and adhesion molecules, such as HLA class I antigens and intercellular adhesion molecule-1 (ICAM-1) [2].

Characterization of the sequence of events triggered by mismatched alloantigens in renal transplant recipients may sharpen our ability to differentiate acute rejection of a kidney graft from other causes of renal dysfunction, thus improving therapeutic decisions and, thereby, the outcome of renal allografts and the survival of their recipients. We therefore, in the present study, performed a retrospective analysis of renal biopsies from three groups of transplant recipients, i.e., those who suffered from acute rejection, those who suffered from renal dysfunction caused by other mechanisms, and those who enjoyed a favorable clinical course.

Patients, materials, and methods

The recipient group included 14 females and 24 males with a mean age of 42.6 years (range 23-62 years). Two recipients had been transplanted with kidneys from living related donors; the remaining 36 recipients had been transplanted with kidneys from postmortal, unrelated donors after matching for maximal HLA compatibility via the Eurotransplant system. All patients were continuously treated with immunosuppressive therapy consisting of cyclosporin A (up to 12 mg/kg daily, according to serum levels) and prednisone (10 mg daily). In addition, patients were treated with methylprednisolone pulse therapy or antithymocyte globulin when they experienced episodes of acute graft rejection. The interval between renal transplantation and biopsy ranged from a minimum of 1 month to a maximum of 12 months.

Renal biopsies were taken with a 2-mm ultrasound-guided needle. Each sample was divided into two parts: one was fixed in 10% buffered formalin, embedded in paraffin, and used for conventional histology; the other one was snap-frozen in liquid nitrogen within 60 min after removal and stored at -70°C until used for immunohistochemistry. Characteristics of the monoclonal antibodies used are summarized in Table 1.

Three-micrometer thick sections of formalin-fixed tissues were stained with hematoxilin-eosin, silver methamine, or periodic acidSchiff, following standard procedures [1]. Each section was analyzed for the parameters listed in Table 2.

Results were classified as extent of expression on components of graft or infiltrate. Thus, positive results meant more than 50% expression, weakly positive meant less than 50% expression, and negative meant no expression on either tissue or cells.

Immunoperoxidase staining of 3-µm thick sections of frozen tissue was performed as follows. The sections of tissue were cut and put on gelatinized glass slides and air-dried. The tissue was then incubated with acetone for a 10-min fixation period. Following three wash steps with phosphate-buffered saline (PBS), the sections were incubated for 30 min at room temperature with 50 µl of the appropriate dilution of the monoclonal antibody (Table 1). Following washing in PBS, the sections were incubated for 30 min at room temperature in 100 µl of horscradish peroxidase (HRP)-conjugated rabbit anti-mouse Ig (Dako, Glostrup, Denmark), diluted 1:60 in PBS containing 1% bovine serum albumin (BSA) and 20% normal human serum (NHS). The sections were again washed three times in PBS and incubated for 30 min at room temperature in 100 µl of swine anti-rabbit Ig (Dako, Glostrup, Denmark). Thereafter, wash steps were repeated three times and 5% 3-amino-9-ethylcarbazol in acetate buffer (37 ml 0.2 M acetic acid, 88 ml 0.2 M Na acetate, 125 ml distilled water), together with H2O2, was added for 5 min, followed by counterstaining with Mayer's hematoxylin.

Table 1. Characteristics of the monoclonal antibodies used

Antibody	Subclass	Source	Reactivity	Reference
DAKO-LCA	IgG2b	DAKO ^a	CD45	Eur J Immunol (1978) 8: 539–551
HB-44	IgG1	ATCC ^h	Monocytes	Proc Nat Acad Sci USA (1980) 77: 6764-6768
HNK-1	IgM	ATCC	CD16	J Immunol (1981) 127: 1024–1029
OKT-3	lgG2b	ATCC	CD3	Cell (1980) 19: 821-828
betaFl	IgG1	TCS ^c	TcR2	[20]
TcRgd1	lgG1	Dr. Borst ^d	TcR1	[21]
TS2/7	IgGi	TCS	VLA-1	J Biol Chem (1987) 262: 3300-3309
Ki-67	IgG1	DAKO	Prolif cells	J Histochem Cytochem (1989) 37: 1471–1479
CL 203.4	IgG1	Dr. Ferrone	ICAM-I	[29]
B8.11.2	lgG2b	Dr. Giphart ^e	HLA-DR	Proc Natl Acad Sci USA (1979) 76: 6567-6571

^a Dakopatts, Glostrup, Denmark

Proliferating cells

* American Type Culture Collection, Rockville, Md., USA

* T Cell Sciences, Cambridge, Mass., USA

^d The Netherlands Cancer Institute, Amsterdam, the Netherlands

14/30 (46.7)

NS

^e University of Leiden, Leiden, the Netherlands

The number of infiltrating cells staining positive with monoclonal antibodies to the first eight markers from Table 1 was scored as the number of stained cells in an area chosen at random over a surface of 0.625 mm^2 , at a magnification of $400 \times$, using a graticule in the eyepiece of the microscope. Sections smaller than 0.625 mm^2 were discarded. Not only was the number of positive-staining cells statistically evaluated, but also the presence or absence of positive-staining cells per se.

Staining with anti-HLA class II and anti-ICAM-1 monoclonal antibodies (Fig. 4) was classified according to the criteria outlined for the histological study. Each tissue specimen was scored by two independent observers without knowledge of the clinical diagnosis. To determine the differences among the three groups of biopsies, statistical analysis of the data was performed utilizing the chi-square test for the qualitative data and an analysis of variance for the quantitative data.

Results

Sixty-two renal biopsies obtained from 38 patients were divided into three groups according to the clinical diagnosis at the time the biopsy was performed. Group 1, classified as acute rejection, included 39 samples from 20 patients with an episode of dysfunction that responded to a full course either of methylprednisolone or of antithymocyte globulin and 4 samples from 4 patients who did not respond to immunosuppressive therapy and who progressively deteriorated for no other identified reason but acute rejection. Group 2, classified as other causes of dysfunction, included ten samples from six patients with renal dysfunction caused by either cyclosporin A toxicity (n = 6, documented by high cyclosporin A levels and asubsequent decrease in serum creatinine after lowering of the cyclosporin dosage), local infarction of the kidney, documented by renal scan (n = 2), infection (n = 1), or unknown reasons (n = 1, a combination of high gentamycin and cyclosporin levels). Group 3, classified as stable function, included nine samples from eight patients without renal dysfunction. Renal dysfunction was defined as a sustained rise in serum creatinine level of more than 20% above the mean of the previous (no less than 2-week) baseline levels or a decline in the rate of improvement of renal function.

0/7(0)

0.0456

istal number of otopada whith the stabled Broup, of the in square test										
Target	Rejection		Other		Stable					
	pos/tot (%)	CHI 1vs2 P	pos/tot (%)	CHI 2vs3 P	pos/tot (%)	CHI 1vs3 P	F P			
Leukocytes (CD45)	35/35 (100)	NS	9/9 (100)	NS	7/7 (100)	NS				
Monocytes/ macrophages	22/34 (64.7)	0.0286	1/7 (14.3)	NS	0/7 (0)	0.0042				
Natural killer cells (CD16)	34/34 (100)	NS	6/8 (75)	NS	4/7 (57.1)	NS				
Lymphocytes (CD3)	33/33 (100)	NS	8/8 (100)	NS	6/6 (100)	NS				
TCR/alpha-beta (TcR2)	32/34 (94.1)	0.0001	2/8 (25)	NS	2/7 (28.6)	0.0003				
TCR/gamma- delta (TcR1)	21/33 (63.6)	0.0093	1/8 (12.5)	NS	1/7 (14.3)	0.0493				
VLA-1	14/34 (41.2)	NS	1/8 (12.5)	NS	0/7(0)	NS				

1/8 (12.5)

NS

Table 2. Expression of cell surface markers in the three studied groups. pos, Number of biopsies within the group positive for the marker; tot, total number of biopsies within the studied group; CHI, chi square test



20-

100

80

60

40

20

Pericapillary

mononuclea

cell infiltrate

(%)



The results of the histological analysis of the samples in the three groups of patients are as follows. The presence of focal infiltrate, hemorrhage, and fibrosis did not correlate with the presence of acute rejection as defined above. Nor did such features as arterial intima proliferation, arterial media proliferation, arterial wall diameter, arterial hyalinosis or glomerular thrombosis, ischemia, or cellularity show any relationship to the presence of acute rejection. However, diffuse interstitial infiltrate, damage to the tubular basement membrane, capillary congestion, and mononuclear infiltrates around capillaries were features seen significantly more often in the biopsies taken during acute rejection than those taken in the other two situations (Fig. 1).

The results of the immunoperoxidase staining of the renal biopsy samples with monoclonal antibodies to markers characteristic of cell types, to T-cell receptors, and to an antigen associated with cell proliferation are as follows. Neither the number of CD16- and VLA-positive cells nor the number of proliferating cells correlated with the presence of rejection. As can be seen in Fig.2, the number of CD45- and CD3-positive cells was related to the



Fig.2. The number of CD45- (\square), CD3- (\blacksquare), TcR2- (\boxtimes), and TcR1- (\boxtimes) positive cells infiltrating biopsies taken during rejection (n = 35), other causes of renal dysfunction (n = 8), and stable renal function (n = 7). Counts are expressed as cells per 0.625 mm² surface area (mean + 1 SD). There is a significant excess of CD45- and CD3-positive cells (P < 0.001, F test, analysis of variance) in the biopsies taken during rejection

presence of rejection (analysis of variance, P < 0.01). Analysis of the presence of "mere positivity" showed that this qualitative parameter gave additional information. As can be seen in Table 2, the presence of monocytes/macrophages, TcR1- and TcR2-positive lymphocytes, and proliferating cells could be found significantly more often during rejection.

In the biopsies from patients without rejection, ICAM-1 was present on glomerular and intertubular capillaries and weakly present on arteriolar and venular endothelial cells. Bowman's capsule stained positive for ICAM-1. During rejection, ICAM-1 expression in the glomeruli increased significantly (P < 0.001) compared with the stable situation; however, the difference between biopsies taken during rejection and during episodes with other causes of renal dysfunction was not statistically significant. Tubular ICAM-1 expression was significantly more often present during rejection in comparison to the group with stable function (P < 0.001) and that with renal function impairment due to other causes (P < 0.001; Fig.3). An example of tubular ICAM-1 staining is shown in Fig.4.

In the control biopsies without rejection, HLA class II staining was strongest for glomerular and endothelial capillaries. Weaker staining of venular endothelial cells was observed and arteriolar endothelium did not stain. However, in half of the biopsies, tubuli were positive as well. Although the percentage of biopsies with HLA class II positive tubuli was higher in the rejecting group, the difference was not statistically significant (Fig. 3).

Discussion

The clinician dealing with renal transplantation usually makes the diagnosis of acute rejection on the basis of a well-described combination of clinical and histological findings [1, 10, 24, 31]. However, the presence of similar histological signs in clinically sound grafts [5, 18], as well as a diminishing abundance of infiltration in later rejections, due to fibrosis, and the influence of the immunosuppressive regimen [19] on the magnitude of infiltrating cells, have cast severe doubt on the validity of these criteria. Therefore, several investigations have evaluated the usefulness of a number of immunological markers in the diagnosis of renal allograft rejection [3, 6, 8, 11, 27–29]. Although the results have been promising, none of the markers is being used routinely to differentiate renal dysfunctions caused by graft rejection from other causes.

In the present study, we analyzed the usefulness of 15 of the most commonly used histological parameters [1], of the composition of the cell infiltrate, and of the expression of ICAM-1 and HLA-DR antigens in the diagnosis of renal graft rejection. In agreement with findings in the literature [1, 10, 24, 31], of the histological parameters investigated, diffuse interstitial infiltration of leukocytes, dam-



Fig. 3. Tubular *ICAM-1* and *HLA-DR* expression during rejection (n = 36), other episodes of renal function deterioration (n = 8), and stable renal function (n = 8). ICAM-1 expression is significantly more often present during rejection episodes (P < 0.0001, chi-square), while the differences for HLA-DR are not significant

age to the tubular basement membrane, and mononuclear leukocytes infiltrating the peritubular capillary wall were found to be the most discriminating.

Immunoperoxidase staining of cell infiltrates with monoclonal antibodies specific for leukocytes, lymphocytes, NK cells, and monocytes/macrophages confirmed previous observations [11, 28] that lymphocytes account for 30%–50% of the leukocyte population. However, analysis of cell infiltrates for their composition and for the expression of VLA and of the MoAb Ki-67-defined proliferation antigen did not provide any useful information for the diagnosis of renal graft rejection. Our results are in agreement with those of Seron et al. [28] with regard to the lack of a diagnostic value of the composition of cell infiltrate, but they differ from theirs with regard to the expression by interstitial cells of the proliferation antigen identified by the MoAb Ki-67. The latter investigators stained renal biopsies with MoAb Ki-67 using a method of gold enhancement of the diaminobenzidine reaction product and they found proliferating cells in the interstitium of kidneys in 15 out of 18 rejection episodes. Therefore, they concluded that identification of proliferating cells could be a useful marker to differentiate rejection from other causes of graft dysfunction. The discrepancy between Seron et al.'s results and our own may reflect the difference in sensitivity of the histochemical procedures used in the two studies, since the use of gold salt may increase the sensitivity of the immunoperoxidase techniques. An alternative possibility that cannot be excluded is the existence of a real difference in the characteristics of the patient population investigated by Seron et al. [28] and by ourselves.

Staining with monoclonal antibodies specific for the beta [25] and for the delta chain [34] of the T-cell receptor showed, for the first time, an increase in the number of CD3-positive cells expressing TcR1 and TcR2, respectively, in renal biopsies from patients with graft rejection. The percentage of TcR1-positive T cells in the renal biopsies during rejection was, on the average, 8.9%. Similar per-



Fig.4a,b. Immunoperoxidase staining with the anti-ICAM-1 MoAb CL 203.4 of frozen sections of renal biopsies. **a** Biopsy taken from functionally stable allograft (immunoperoxidase staining

 \times 100). **b** Biopsy taken during clinically defined acute rejection episode (immunoperoxidase staining \times 250). Differential staining is mainly restricted to the proximal tubular cells

centages have been found in other inflammatory infiltrates in nonlymphoid tissues [25]. Only in granulomatous inflammatory infiltrates have higher percentages been observed [21]. TcR1-positive T cells cultured from transplanted hearts in humans have been reported not to be cytotoxic [15]. Thus, the function of TcR1-positive cells in allografts is not known. From Fig. 2 it is clear that the sum of the number of TcR1- and TcR2-positive T cells in the biopsies from the three studied patient groups is less than the number of CD3-positive cells. In preliminary experiments (data not shown) applying beta F1 and TcRgd1 monoclonal antibodies on peripheral blood mononuclear cells (PBLs) from healthy controls, the same phenomenon was observed. FACS analysis of the same PBLs using the WT31 instead of the beta F1 monoclonal antibody revealed a significantly higher number of TcR2-positive cells, resulting in the disappearance in the gap between the sum of the TcR1- and TcR2-positive cells and the number of CD3-positive cells.

Thus, counting of beta F1-stained sections results in false, low values for TcR2-positive cells. Unfortunately, other more sensitive monoclonal antibodies reacting with TcR2-positive cells in tissue sections are, to our knowl-edge, unavailable at this time.

Adhesion molecules have been shown to play an important role in the interaction of cytotoxic T cells with their targets [2, 7, 9, 32]. Furthermore, our group has recently shown that antilymphocyte function-associated molecule-1 (LFA-1) monoclonal antibodies inhibit the donor-specific lysis of proximal tubular epithelial cells [20, 33]. Therefore, we tested renal biopsies for the expression of ICAM-1, which is the ligand of LFA-1, and we compared its expression with that of HLA class II antigens. Like ICAM-1 [23], HLA class II antigens are not normally expressed on renal tubular cells [22] and are susceptible to modulation by cytokines [16, 17, 33]. Furthermore, it has been suggested that the appearance of HLA class II antigens on renal tubular cells might be a useful marker to differentiate between rejection and other causes of renal graft dysfunction [2]. In agreement with the results recently reported by Faull and Russ [9], we detected ICAM-1 in tubular cells during renal allograft rejection.

ICAM-1 expression is significantly associated with rejection. This conclusion is at variance with that by Faull and Russ [9], who question the usefulness of this marker for the diagnosis of renal graft rejection, since they detected it in several biopsies without apparent rejection. However, the number of biopsies with rejection studied by us (n = 36) is considerably larger than the number in Faull and Russ's study (n = 8). This may explain why, in our study, statistical significance (P < 0.001) could be reached in the absence of ICAM-1-negative tubules in biopsies taken during rejection. We recognize that our results need to be confirmed in a larger, prospective study in which biopsies are taken irrespective of renal function and therapy. Until the results of such a study are known, classical histological abnormalities, such as diffuse interstitial infiltrates, tubular basement membrane involvement, capillary congestion, and pericapillary mononuclear cell infiltrate, will certainly increase the likelihood of rejection. Tubular ICAM-1 expression may be at least as valuable for the clinician, as it was the most sensitive marker for rejection in this study. Thus far, the absence of tubular ICAM-1 expression seems to exclude rejection.

Acknowledgements. This study was supported by grant C87.0706 from the Dutch Kidney Foundation and by grants AI21384, CA37959, and CA39559 from the National Institute of Health.

References

- Bergstrand B, Bohman SO, Farnsworth A, Gokel JM, Krause PH, Lang W, Mihatsch MJ, Oppedal B, Sell S, Sibley RK, Thiru S, Verani R, Wallace AC, Zollinger HU, Ryffel B, Thiel G, Wonigeit K (1985) Renal histopathology in kidney transplant recipients immunosuppressed with cyclosporin A: results of an international workshop. Clin Nephrol 24: 107–118
- Bishop GA, Hall BM (1989) Expression of leucocyte and lymphocyte adhesion molecules in the human kidney. Kidney Int 36: 1078–1085
- Bogman MJJT, Winkel JGJ van de, Hoitsma AJ, Ruiter DJ, Dooper IMM, Tax WJM, Assman KJM, Koene RAP (1989) Diagnosis of renal allograft rejection by macrophage immunostaining with a CD14 monoclonal antibody, WT14. Lancet II: 235-238
- Boog CJP, Boes J, Melief CJM (1988) Stimulation with dendritic cells decreases or obviates the Cd4 + helper cell requirement in cytotoxic T lymphocyte responses. Eur J Immunol 18: 219–223
- 5. Burdick JF, Beschorner WE, Smith WJ, McGraw D, Bender W, Williams GM, Solez K (1984) Characteristics of early routine renal allograft biopsies. Transplantation 38: 679–684
- 6. Colvin RB (1988) Clinical applications of monoclonal antibodies in renal allograft biopsies. Am J Kidney Dis 11: 126–130
- Dustin ML, Springer TA (1989) T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature 341: 619–624
- Es A van, Meyer CJLM, Oljans PJ, Tanke HJ, Es LA van (1984) Mononuclear cells in renal allografts: correlation with peripheral blood T lymphocyte subpopulations and graft prognosis. Transplantation 37: 134–139
- Faull RJ, Russ GR (1989) Tubular expression of intercellular adhesion molecule-1 during renal allograft rejection. Transplantation 48: 227–230
- Finkelstein FO, Siegel NJ, Bastl C, Forest JN Jr, Kashgarian M (1976) Kidney transplant biopsies in the diagnosis and management of acute rejection episodes. Kidney Int 10: 171–178
- Hancock WW (1984) Analysis of intragraft effector mechanisms associated with human renal allograft rejection: immunohistological studies with monoclonal antibodies. Immunol Rev 77: 61– 84
- 12. Harel-Bellan A, Bertoglio J, Quillet A, Marchiol C, Wakasugi H, Mishall Z, Fradelizi D (1986) Interleukin 2 upregulates its own receptor on a subset of human unprimed peripheral blood lymphocytes and triggers their proliferation. J Immunol 136: 2463– 2469
- Inaba K, Steinman RM (1986) Accessory cell T lymphocyte interactions. Antigen dependent and independent clustering. J Exp Med 163: 247–261
- Inaba K, Young JW, Steinman RM (1987) Direct activation of CD8⁺ cytotoxic T lymphocytes by dendritic cells. J Exp Med 166: 182–194
- 15. Jutte NPHM, Kerckhove BAE van de, Ouwehand AJ, Baan CC, Bos E, Claas FHJ, Weimar W (1990) Gamma delta TCR + T cell clones derived from heart transplant recipients do not show donor specific cytotoxicity. Hum Immunol 28: 170–174
- 16. Maio M, Gulwani B, Tombesi S, Langer JA, Duigou GJ, Kerbel RS, Fischer PB, Ferrone S (1988) Differential induction by immune interferon of the gene products of the HLA-D region on

- 17. Maio M, Gulwani B, Langer JA, Kerbel RS, Duigou GJ, Fisher PB, Ferrone S (1989) Modulation by interferons of HLA antigen, high-molecular-weight melanoma-associated antigen, and intercellular adhesion molecule 1 expression by cultured melanoma cells with different metastatic potential. Cancer Res 49: 2980-2987
- McWhinnie DL, Thompson J, Taylor HM, Chapman JR, Bolton EM, Wood RFM, Morris PJ (1985) Leukocyte infiltration patterns in renal allografts assessed by immunoperoxidase staining of 245 sequential biopsies. Transplant Proc 17: 560-561
- McWhinnie DL, Fuggle SV, Azevedo LS, Morris PJ (1987) HLA class II induction and cellular infiltration are efficiently suppressed by triple therapy in renal allografts. Transplant Proc 19: 3628-3629
- 20. Miltenburg AMM, Meijer-Paape ME, Daha MR, Bockel JH van, Weening JJ, Es LA van, Woude FJ van der (1989) Donor-specific lysis of human kidney proximal tubular epithelial cells by renal allograft infiltrating lymphocytes. Transplantation 48: 296–302
- Modlin RL, Pirmze C, Hofman FM, Torigian V, Uyemura K, Rea TH, Bloom BR, Brenner MB (1989) Lymphocytes bearing antigen-specific gamma-delta T-cell receptors accumulate in human infectious disease lesions. Nature 339: 544-548
- Natali PG, De Martino C, Marcellini M, Quaranta V, Ferrone S (1981) Expression of Ia-like antigens on the vasculature of human kidney. Clin Immunol Immunopathol 20: 11-20
- 23. Natali PG, Nicotra MR, Cavaliere R, Bigotti A, Romano G, Temponi M, Ferrone S (1990) Differential expression of intercellular adhesion molecule-1 in primary and metastatic melanoma lesions. Cancer Res 50: 1271–1278
- 24. Parfrey PS, Kuo YL, Hanley JA, Knaack J, Xue Z, Lisbona R, Guttmann RD (1984) The diagnostic and prognostic value of renal allograft biopsy. Transplantation 38: 586–590
- 25. Picker IJ, Brenner MB, Weiss LM, Smith SD, Warnke RA (1987) Discordant expression of CD3 and T-cell receptor beta-chain antigens in T-lineage lymphomas. AJP 129: 434-440

- Rollinghof M, Pfizenmaier K, Wagner H (1982) T-T cell interactions during cytotoxic T cell responses. Eur J Immunol 12: 337– 342
- 27. Sako H, Nakane Y, Okino K, Nishihara K, Kodama M, Paku K, Takayama H, Tomoyshi T, Kawata M, Yamada H (1987) Immunohistochemical study of the cells infiltrating human renal allografts by the ABC and the IGSS method using monoclonal antibodies. Transplantation 44: 43–50
- Seron D, Alexopoulos E, Raftery MJ, Hartley RB, Cameron JS (1989) Diagnosis of rejection in renal allograft biopsies using the presence of activated and proliferating cells. Transplantation 47: 811-816
- 29. Totterman H, Hanas E, Bergstrom R, Larsson E, Tufveson G (1989) Immunologic diagnosis of kidney rejection using facs analysis of graft-infiltrating functional and activated T and NK cell subsets. Transplantation 47: 817–823
- 30. Tsujisaki M, Igarashi M, Sakaguchi K, Eisinger M, Herlyn M, Ferrone S (1987) Immunochemical and functional analysis of HLA Class II antigens induced by recombinant immune interferon on normal epidermal melanocytes. J Immunol 138: 1310– 1316
- Vagelista A, Frasca GM, Stefoni S, Bonomini V (1983) Graft biopsy in renal transplantation: correlation with clinical, immunological, and virological investigations. Kidney Int 23 [Suppl 14]: S41-S45
- 32. Wawryk SO, Novotny JR, Wicks IP, Wilkinson D, Maher D, Salvaris E, Welch K, Fecondo J, Boyd AW (1989) The role of the LFA-1/ICAM-1 interaction in human leukocyte homing and adhesion. Immunol Rev 108: 135-161
- 33. Woude FJ van der, Daha MR, Miltenburg AMM, Meyer-Paape ME, Bruijn JA, Bockel HJ van, Es LA van (1990) Renal allograft-infiltrated lymphocytes and proximal tubular cells: further analysis of donor specific lysis. Hum Immunol 28: 186–192
- 34. Wu YJ, Tian WT, Snider RM, Rittershaus C, Rogers P, LaManna L, Ip SH (1988) Signal transduction of gamma/delta cell antigen receptor with a novel mitogenic anti-delta antibody. J Immunol 141: 1476–1479